Dr. Andrew Tutt

Biography

Andrew Tutt qualified in Medicine in 1990 and completed his postgraduate training in General Medicine and Clinical Oncology at the Royal Marsden Hospital. He gained a Predoctoral Research Training Fellowship from the Medical Research Council, working in Professor Alan Ashworth’s laboratory at the Institute of Cancer Research. His research focused on the DNA repair functions of the BRCA2 breast cancer predisposition gene and its role in homologous recombination. He was awarded a PhD in 2002. As a Clinician Scientist, he identified synthetic lethality in PARP inhibitors linked to BRCA1/2 mutations. He has led clinical trial programs focusing on triple-negative breast cancer (TNBC) associated with functional deficiencies in BRCA1 and BRCA2, and developed single-agent PARP inhibitor trials. He holds directorships at the Breast Cancer Research Unit at King's College London and is a consultant oncologist at Guy’s and St Thomas’ NHS Foundation Trusts. Notably, he chaired the St Gallen Early Breast Cancer International Consensus Panel and has significantly shaped clinical practice guidelines for patients with BRCA1 and BRCA2 mutated breast cancer. He has received several prestigious awards, including the ESMO Breast Cancer Award in 2021 and the Addarii Award from the University of Bologna in 2015, reflecting his significant contributions to breast cancer research.

Research Interests